Palvella Therapeutics (PVLA) Long-Term Investments (2017 - 2022)

Palvella Therapeutics (PVLA) has reported Long-Term Investments for 5 consecutive years, with $4.5 million the latest figure, recorded in Q2 2022.

• In Q2 2022, Long-Term Investments changed N/A year-over-year to $4.5 million; the TTM figure through Jun 2022 stood at $4.5 million (changed N/A YoY), while the FY2019 annual figure was $28.6 million, up 397.46% from the prior year.
• Long-Term Investments eased to $4.5 million in Q2 2022 per PVLA's latest filing, from $9.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $38.9 million in Q1 2019 and bottomed at $700000.0 in Q2 2018.
• Historically, Long-Term Investments has averaged $10.4 million across 4 years, with a median of $5.7 million in 2018.
• Annual changes were most pronounced in 2019 — Long-Term Investments soared 1406.93% — and 2020, when it slumped 85.32%.
• Palvella Therapeutics' Long-Term Investments stood at $5.8 million in 2018, then soared by 397.46% to $28.6 million in 2019, then plunged by 68.58% to $9.0 million in 2020, then sank by 49.54% to $4.5 million in 2022.
• Business Quant data shows PVLA's Long-Term Investments at $4.5 million in Q2 2022, $9.0 million in Q3 2020, and $1.6 million in Q2 2020.